Wayne Ho
Internal Medicine · Los Angeles, CANPI 1477731867
Payments from drug & device makers
Across 698 payments — averaging $315.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$172K
- Eli Lilly$16K
- Viiv Healthcare Company$10K
- Sanofi-aventis U.S. LLC$6K
- Gilead$5K
- Pfizer$1K
- plus $10K from 45 others
Across 24 payments — averaging $937.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$19K
- Sanofi US Services Inc.$4K
What the payments were for
- Consulting fees$7,99027%
- Speaking & faculty fees$2561%
- Travel & lodging$3,09811%
- Food & beverage$17,72861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$220,080 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 87 | $330,162 |
| TivicayDolutegravir Sodium | 38 | $81,716 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $59,997 |
| PrezcobixDarunavir/Cobicistat | 23 | $55,587 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $48,207 |
| MounjaroTirzepatide | 44 | $47,586 |
| PifeltroDoravirine | 19 | $44,780 |
| OzempicSemaglutide | 20 | $17,926 |
| TrintellixVortioxetine Hydrobromide | 23 | $10,366 |
| LinzessLinaclotide | 13 | $7,085 |
| Testosterone | 22 | $5,918 |
| QnaslBeclomethasone Dipropionate | 11 | $3,227 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,621 |
| Tadalafil | 23 | $1,583 |
| Omega-3 Acid Ethyl Esters | 20 | $1,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $5,421 | $330,16287 claims |
| Viiv Healthcare CompanyTivicay, Dovato | $10,024 | $141,71458 claims |
| Johnson & JohnsonPrezcobix | $872 | $55,58723 claims |
| Lilly USA, LLCMounjaro | $959 | $47,58644 claims |
| MerckPifeltro | $490 | $44,78019 claims |
| Novo NordiskOzempic | $248 | $17,92620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $94 | $10,36623 claims |
| AbbVieLinzess, Synthroid | $883 | $8,30324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.